

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT
CLOSING OF THE EXCLUSIVE GLOBAL LICENSING AGREEMENT
BETWEEN LEGEND BIOTECH AND NOVARTIS

Reference is made to the announcement of Genscript Biotech Corporation (the “**Company**”) dated 13 November 2023 (the “**Announcement**”) in relation to Legend Biotech’s entering into an exclusive worldwide license agreement with Novartis. Unless otherwise defined, all capitalized terms used herein shall have the same meanings as defined in the Announcement.

Legend Biotech Corporation (“**Legend**”), a non-wholly owned subsidiary of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the U.S., has announced that, on 3 January 2024 (New York Time), Legend closed the License Agreement with Novartis for certain Legend chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand protein 3 (DLL3), including Legend’s existing autologous CAR-T cell therapy candidate which Legend Biotech refers to as “LB2102”. Under the terms of the License Agreement, Legend will receive a US\$100 million upfront cash payment.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By Order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 3 January 2024

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

** For identification purposes only*